Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Clinical trial NCT03546426 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03546426
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-12
- Primary completion
- 2027-01-01
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.